Assessment of insulin sensitivity in adults with permanent neonatal diabetes mellitus due to mutations in the KCNJ11 gene encoding Kir6.2
- PMID: 17491708
- PMCID: PMC1783575
- DOI: 10.1900/RDS.2006.3.17
Assessment of insulin sensitivity in adults with permanent neonatal diabetes mellitus due to mutations in the KCNJ11 gene encoding Kir6.2
Abstract
Activating mutations in the KCNJ11 gene encoding the Kir6.2 subunit of ATP-sensitive potassium channel have been described in patients with permanent neonatal diabetes mellitus (PNDM). The main pathophysiological feature of PNDM associated with Kir6.2 mutations is a profound defect in insulin secretion. However, the expression of Kir6.2 protein is not limited to beta-cells; it also includes skeletal muscles, heart, brain, and peripheral nerves. Thus, the hypothesis that Kir6.2 mutations may influence insulin sensitivity in humans seems justified. Moreover, this notion is additionally supported by an animal model of Kir6.2 knock-out mice. Four adult carriers of a Kir6.2 mutation from the Polish population (mean age 31.5 years, range 20-50) were available for this study that aimed to evaluate their insulin sensitivity by the hyperinsulinemic euglycemic clamp technique. Three subjects carried the R201H mutation and one patient was a carrier of the K170N mutation. In addition, eight healthy volunteers with normal glucose tolerance were examined for comparison (mean age 31.0 years, range 20-41). The mean M value, i.e. the amount of metabolized glucose, for PNDM cases equaled 4.49 mg/(kg x min) (range 2.76-6.66) and was significantly lower than in the control group (9.64 mg/(kg x min), range 4.59-18.00). This observation suggests that impaired insulin sensitivity, in addition to profoundly decreased insulin secretion, contributes to the clinical picture of PNDM resulting from mutations in the Kir6.2 gene. An additional factor that might influence insulin sensitivity in our diabetes patients is glucose toxicity that may have appeared due to poor metabolic control prior to the examination (mean HbA1c = 8.95%). The intriguing question to be answered in the future is whether an improvement in insulin action could be seen following the transfer of Kir6.2 mutation carriers to sulphonylurea compounds.
Similar articles
-
KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes.Hum Mutat. 2005 Jan;25(1):22-7. doi: 10.1002/humu.20124. Hum Mutat. 2005. PMID: 15580558
-
[Low doses of sulphonyluria as a successful replacement for insulin therapy in a patient with neonatal diabetes due to a mutation of KCNJ11 gene encoding Kir6.2].Lijec Vjesn. 2010 Mar-Apr;132(3-4):90-3. Lijec Vjesn. 2010. PMID: 20540435 Croatian.
-
Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.Diabetes Metab. 2006 Dec;32(6):569-80. doi: 10.1016/S1262-3636(07)70311-7. Diabetes Metab. 2006. PMID: 17296510 Review.
-
[Glycemic index of meals and postprandial glycemia in patients with permanent neonatal diabetes due to Kir6.2 gene mutations].Przegl Lek. 2007;64(6):398-400. Przegl Lek. 2007. PMID: 18159846 Polish.
-
Neonatal diabetes mellitus: a disease linked to multiple mechanisms.Orphanet J Rare Dis. 2007 Mar 9;2:12. doi: 10.1186/1750-1172-2-12. Orphanet J Rare Dis. 2007. PMID: 17349054 Free PMC article. Review.
Cited by
-
Neonatal diabetes mellitus.Endocr Rev. 2008 May;29(3):265-91. doi: 10.1210/er.2007-0029. Epub 2008 Apr 24. Endocr Rev. 2008. PMID: 18436707 Free PMC article. Review.
-
The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes.Pharmgenomics Pers Med. 2010;3:145-61. doi: 10.2147/PGPM.S6969. Epub 2010 Nov 24. Pharmgenomics Pers Med. 2010. PMID: 23226049 Free PMC article.
-
Phenotype variability and neonatal diabetes in a large family with heterozygous mutation of the glucokinase gene.Acta Diabetol. 2011 Sep;48(3):203-8. doi: 10.1007/s00592-011-0279-8. Epub 2011 Mar 25. Acta Diabetol. 2011. PMID: 21437567 Free PMC article.
-
Use of a long-term continuous glucose monitor for predicting sulfonylurea dose in patients with neonatal diabetes mellitus: a case series.Clin Pediatr Endocrinol. 2024;33(3):131-138. doi: 10.1297/cpe.2023-0062. Epub 2025 Mar 8. Clin Pediatr Endocrinol. 2024. PMID: 38993723 Free PMC article.
-
The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy.J Clin Endocrinol Metab. 2008 Mar;93(3):1054-61. doi: 10.1210/jc.2007-1826. Epub 2007 Dec 11. J Clin Endocrinol Metab. 2008. PMID: 18073297 Free PMC article.
References
-
- Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004;350:1838–1849. - PubMed
-
- Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes. 2005;54:2503–2513. - PubMed
-
- Klupa T, Edghill EL, Nazim J, Sieradzki J, Ellard S, Hattersley AT, Malecki MT. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation. Diabetologia. 2005;48:1029–1031. - PubMed
-
- Miki T, Minami K, Zhang L, Morita M, Gonoi T, Shiuchi T, Minokoshi Y, Renaud JM, Seino S. ATP-sensitive potassium channels participate in glucose uptake in skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab. 2002;283:E1178–E1184. - PubMed
-
- Brackenridge A, Pearson ER, Shojaee-Moradie F, Hattersley AT, Russell-Jones D, Umpleby AM. Contrasting insulin sensitivity of endogenous glucose production rate in subjects with hepatocyte nuclear factor-1beta and -1alpha mutations. Diabetes. 2006;55:405–411. - PubMed
LinkOut - more resources
Full Text Sources